Current pharmacotherapy of bradykinin-mediated angioedema

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 5, 2013, Pages 571-586

  Farkas, Henriette ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Antifibrinolytics; Attenuated androgens; Bradykinin B2 receptor antagonist; Bradykinin mediated angioedema; Kallikrein inhibitor; Plasma derived C1 inhibitor concentrate; Recombinant human C1 inhibitor concentrate; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; AMINOCAPROIC ACID; ANDROGEN; ANTIFIBRINOLYTIC AGENT; CETOR; COMPLEMENT COMPONENT C1S INHIBITOR; DANAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ECALLANTIDE; ESTROGEN; FRESH FROZEN PLASMA; GESTAGEN; ICATIBANT; LIDOCAINE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLTESTOSTERONE; NONSTEROID ANTIINFLAMMATORY AGENT; OXANDROLONE; PLACEBO; PROGESTERONE; STANOZOLOL; TRANEXAMIC ACID; UNCLASSIFIED DRUG;

AGGRESSION; ALOPECIA; ANGIONEUROTIC EDEMA; ANTIHYPERTENSIVE THERAPY; COMPLEMENT ACTIVATION; DEPRESSION; DIARRHEA; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DYSMENORRHEA; ERYTHROCYTE COUNT; ESSENTIAL HYPERTENSION; ESTROGEN THERAPY; FATIGUE; FLUSHING; GAIN OF FUNCTION MUTATION; HEART ARRHYTHMIA; HEMATOCRIT; HEMATURIA; HEMOGLOBIN BLOOD LEVEL; HIRSUTISM; HUMAN; HYPERTENSION; HYPOMANIA; INTRAOCULAR HYPERTENSION; LIBIDO; MANIA; MENSTRUATION DISORDER; MOLECULAR PATHOLOGY; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OBSTRUCTIVE JAUNDICE; ORTHOSTATIC HYPOTENSION; PRIMARY PREVENTION; PSYCHOSIS; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TOXIC HEPATITIS; VERTIGO; VOICE; WEIGHT GAIN;

ANDROGENS; ANTIFIBRINOLYTIC AGENTS; BRADYKININ; CAPILLARY PERMEABILITY; COMPLEMENT C1 INHIBITOR PROTEIN; HEREDITARY ANGIOEDEMA TYPE III; HEREDITARY ANGIOEDEMA TYPES I AND II; HUMANS; RECEPTORS, BRADYKININ; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84874984507     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.778826     Document Type: Review

References (173)

1. Kaplan AP. Angioedema. World Allergy Organ J 2008;1(6):103-13.
2. Agostoni A, Aygoren-Pursun E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol 2004;114(3 Suppl):S51-131.
3. Frigas E, Park MA. Acute urticaria and angioedema: diagnostic and treatment considerations. Am J Clin Dermatol 2009;10(4):239-50
4. Maurer M, Bader M, Bas M, et al. New topics in bradykinin research. Allergy 2011;66(11):1397-406.
5. Farkas H, Harmat G, Fay A, et al. Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema. Acta Derm Venereol 2001;81(5):376-7
6. Temino VM, Peebles RS Jr. The spectrum and treatment of angioedema. Am J Med 2008;121(4):282-6
7. Zuraw BL. Clinical practice. Hereditary angioedema. N Engl J Med 2008;359(10):1027-36
8. Cicardi M, Zanichelli A. Acquired angioedema. Allergy Asthma Clin Immunol 2010;6(1):14
9. Makani H, Messerli FH, Romero J, et al. Meta-analysis of randomized trials of angioedema as an adverse event of renin-angiotensin system inhibitors. Am J Cardiol 2012;110(3):383-91.
10. Zingale LC, Beltrami L, Zanichelli A, et al. Angioedema without urticaria: a large clinical survey. CMAJ 2006;175(9):1065-70
11. Bas M, Adams V, Suvorava T, et al. Nonallergic angioedema: role of bradykinin. Allergy 2007;62(8):842-56.
12. Renne T, Schmaier AH, Nickel KF, et al. In vivo roles of factor XII. Blood 2012;120(22):4296-303
13. Kaplan AP, Ghebrehiwet B. The plasma bradykinin-forming pathways and its interrelationships with complement. Mol Immunol 2010;47(13):2161-9
14. Nussberger J, Cugno M, Cicardi M, Agostoni A. Local bradykinin generation in hereditary angioedema. J Allergy Clin Immunol 1999;104(6):1321-2
15. Moreau ME, Garbacki N, Molinaro G, et al. The kallikrein-kinin system: current and future pharmacological targets. J Pharmacol Sci 2005;99(1):6-38
16. Fryer RM, Segreti J, Banfor PN, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy of enzymes associated with bradykinin-mediated angioedema. Br J Pharmacol 2008;153(5):947-55
17. Bossi F, Fischetti F, Regoli D, et al. Novel pathogenic mechanism and therapeutic approaches to angioedema associated with C1 inhibitor deficiency. J Allergy Clin Immunol 2009;124(6):1303-10; e4
18. Rosen FS, Pensky J, Donaldson V, Charache P. Hereditary angioneurotic edema: two genetic variants. Science 1965;148(3672):957-8
19. Longhurst H, Cicardi M. Hereditary angio-oedema. Lancet 2012;379(9814):474-81
20. Kaplan AP, Joseph K. Kinin formation in C1 inhibitor deficiency. J Allergy Clin Immunol 2010;125(6):1411-12; author reply 12
21. van Geffen M, Cugno M, Lap P, et al. Alterations of coagulation and fibrinolysis in patients with angioedema due to C1-inhibitor deficiency. Clin Exp Immunol 2012;167(3):472-8
22. Binkley KE, Davis A III. Clinical, biochemical, and genetic characterization of a novel estrogen-dependent inherited form of angioedema. J Allergy Clin Immunol 2000;106(3):546-50
23. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000;356(9225):213-17
24. Longhurst HJ, Farkas H, Craig T, et al. HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010;6(1):22
25. Cichon S, Martin L, Hennies HC, et al. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III. Am J Hum Genet 2006;79(6):1098-104
26. Cugno M, Castelli R, Cicardi M. Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferation. Autoimmun Rev 2008;8(2):156-9
27. Mandle R, Baron C, Roux E, et al. Acquired C1 inhibitor deficiency as a result of an autoantibody to the reactive center region of C1 inhibitor. J Immunol 1994;152(9):4680-5
28. Alsenz J, Loos M. The acquired C1-INH deficiencies with autoantibodies (AAE type II). Behring Inst Mitt 1989(84):165-72
29. Cugno M, Nussberger J, Cicardi M, Agostoni A. Bradykinin and the pathophysiology of angioedema. Int Immunopharmacol 2003;3(3):311-17
30. Hoover T, Lippmann M, Grouzmann E, et al. Angiotensin converting enzyme inhibitor induced angio-oedema: a review of the pathophysiology and risk factors. Clin Exp Allergy 2010;40(1):50-61.
31. McDowell SE, Coleman JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006;332(7551):1177-81
32. Toh S, Reichman ME, Houstoun M, et al. Comparative risk for angioedema associated with the use of drugs that target the renin-angiotensin-aldosterone system. Arch Intern Med 2012;172(20):1582-9
33. Schiller PI, Messmer SL, Haefeli WE, et al. Angiotensin-converting enzyme inhibitor-induced angioedema: late onset, irregular course, and potential role of triggers. Allergy 1997;52(4):432-5
34. Banerji A, Oren E, Hesterberg P, et al. Ten-year study of causes of moderate to severe angioedema seen by an inpatient allergy/immunology consult service. Allergy Asthma Clin Immunol 2008;29(1):88-92
35. Campos MM, Calixto JB. Neurokinin mediation of edema and inflammation. Neuropeptides 2000;34(5):314-22
36. Craig T, Pursun EA, Bork K, et al. WAO Guideline for the Management of Hereditary Angioedema. World Allergy Organ J 2012;5(12):182-99.
37. Bowen T, Cicardi M, Farkas H, et al. 2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema. Allergy Asthma Clin Immunol 2010;6(1):24.
38. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012;67(2):147-57.
39. Caballero T, Farkas H, Bouillet L, et al. International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. J Allergy Clin Immunol 2012;129(2):308-20
40. Zuraw BL, Bork K, E Binkley K, et al. Hereditary angioedema with normal C1 inhibitor function: consensus of an international expert panel. Allergy Asthma Proc 2012
41. Wilson DA, Bork K, Shea EP, et al. Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104(4):314-20
42. Bork K, Meng G, Staubach P, Hardt J. Hereditary angioedema: new findings concerning symptoms, affected organs, and course. Am J Med 2006;119(3):267-74
43. Nzeako UC, Longhurst HJ. Many faces of angioedema: focus on the diagnosis and management of abdominal manifestations of hereditary angioedema. Eur J Gastroenterol Hepatol 2012;24(4):353-61
44. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012;130(3):692-7
45. Stojiljkovic L. Renin-angiotensin system inhibitors and angioedema: anesthetic implications. Curr Opin Anaesthesiol 2012;25(3):356-62
46. Farkas H. Management of upper airway edema caused by hereditary angioedema. Allergy Asthma Clin Immunol 2010;6(1):19
47. Bork K. Current management options for hereditary angioedema. Curr Allergy Asthma Rep 2012;12(4):273-80
48. Gompels MM, Lock RJ. Cinryze (C1- inhibitor) for the treatment of hereditary angioedema. Expert Rev Clin Immunol 2011;7(5):569-73
49. Groner A, Nowak T, Schafer W. Pathogen safety of human C1 esterase inhibitor concentrate. Transfusion 2012;52(10):2104-12
50. Hofstra JJ, Kleine Budde I, van Twuyver E, et al. Treatment of hereditary angioedema with nanofiltered C1-esterase inhibitor concentrate (Cetor (R)): multi-center phase II and III studies to assess pharmacokinetics, clinical efficacy and safety. Clin Immunol 2012;142(3):280-90
51. Varga L, Farkas H. rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency. Expert Rev Clin Immunol 2011;7(2):143-53
52. van Veen HA, Koiter J, Vogelezang CJ, et al. Characterization of recombinant human C1 inhibitor secreted in milk of transgenic rabbits. J Biotechnol 2012;162(2-3):319-26
53. Farkas H, Varga L. Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency. Clin Cosmet Investig Dermatol 2011;4:61-8
54. Bas M. Clinical efficacy of icatibant in the treatment of acute hereditary angioedema during the FAST-3 trial. Expert Rev Clin Immunol 2012;8(8):707-17
55. Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema. Ann Allergy Asthma Immunol 2007;98(4):383-8
56. Galan HL, Reedy MB, Starr J, Knight AB. Fresh frozen plasma prophylaxis for hereditary angioedema during pregnancy. A case report. J Reprod Med 1996;41(7):541-4
57. Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med 2001;161(5):714-18
58. Farkas H, Jakab L, Temesszentandrasi G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007;120(4):941-7
59. Berinert [C1 Esterase Inhibitor (Human)] Package Insert. 2011.Available from: http://www.fda.gov/ downloads/BiologicsBloodVaccines/ BloodBloodProducts/ ApprovedProducts/ LicensedProductsBLAs/ FractionatedPlasmaProducts/ UCM186268.pdf
60. Farkas H, Csuka D, Zotter Z, et al. Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients. J Allergy Clin Immunol 2013;131(3):909-911.e5
61. Czaller I, Visy B, Csuka D, et al. The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey. Eur J Obstet Gynecol Reprod Biol 2010;152(1):44-9
62. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009;124(4):801-8
63. Varga L, Fust G, Csuka D, Farkas H. Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema. Mol Immunol 2011;48(4):572-6
64. Craig TJ, Wasserman RL, Levy RJ, et al. Prospective study of rapid relief provided by C1 esterase inhibitor in emergency treatment of acute laryngeal attacks in hereditary angioedema. J Clin Immunol 2010;30(6):823-9
65. Cinryze Package Insert. 2012.Available from: http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/ 001207/WC500108895.pdf
66. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010;363(6):513-22
67. Ruconest Package Insert. 2012.Available from: http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/ 001223/WC500098542.pdf
68. Moldovan D, Reshef A, Fabiani J, et al. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: european open-label extension study. Clin Exp Allergy 2012;42(6):929-35
69. Ecallantide. 2009.Available from: http://www.fda.gov/ downloads/advisorycommittees/ committeesmeetingmaterials/drugs/ pulmonaryallergydrugsadvisorycommittee/ ucm170334.pdf
70. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010;363(6):523-31
71. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104(6):523-9
72. Stolz LE, Sheffer AL. Prospective, double-blind, placebo-controlled trials of ecallantide for acute attacks of hereditary angioedema. Expert Rev Clin Immunol 2012;8(1):25-32
73. MacGinnitie AJ, Campion M, Stolz LE, Pullman WE. Ecallantide for treatment of acute hereditary angioedema attacks: analysis of efficacy by patient characteristics. Allergy Asthma Proc 2012;33(2):178-85
74. Firazyr Package Insert. 2012.Available from: http://www.ema. europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/ 000899/WC500022966.pdf
75. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010;363(6):532-41
76. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B(2) receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011;107(6):529-37
77. Boccon-Gibod I, Bouillet L. Safety and efficacy of icatibant self-administration for acute hereditary angioedema. Clin Exp Immunol 2012;168(3):303-7
78. Farkas H, Csuka D, Zotter Z, et al. Home treatment of hereditary angioedema with icatibant administered by health care professionals. J Allergy Clin Immunol 2012;129(3):851-2; e2
79. Bygum A, Andersen KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009;19(2):147-51
80. Bouillet L, Ponard D, Rousset H, et al. A case of hereditary angio-oedema type III presenting with C1-inhibitor cleavage and a missense mutation in the F12 gene. Br J Dermatol 2007;156(5):1063-5
81. Prieto A, Tornero P, Rubio M, et al. Missense mutation Thr309Lys in the coagulation factor XII gene in a Spanish family with hereditary angioedema type III. Allergy 2009;64(2):284-6
82. Bell CG, Kwan E, Nolan RC, Baumgart KW. First molecular confirmation of an Australian case of type III hereditary angioedema. Pathology 2008;40(1):82-3
83. Bork K, Wulff K, Hardt J, et al. Hereditary angioedema caused by missense mutations in the factor XII gene: clinical features, trigger factors, and therapy. J Allergy Clin Immunol 2009;124(1):129-34
84. Bouillet L, Boccon-Gibod I, Ponard D, et al. Bradykinin receptor 2 antagonist (icatibant) for hereditary angioedema type III attacks. Ann Allergy Asthma Immunol 2009;103(5):448
85. Cronin JA, Maples KM. Treatment of an acute attack of type III hereditary angioedema with ecallantide. Ann Allergy Asthma Immunol 2012;108(1):61-2
86. Cicardi M, Zingale LC, Pappalardo E, et al. Autoantibodies and lymphoproliferative diseases in acquired C1-inhibitor deficiencies. Medicine (Baltimore) 2003;82(4):274-81
87. Bright P, Dempster J, Longhurst H. Successful treatment of acquired C1 inhibitor deficiency with icatibant. Clin Exp Dermatol 2010;35(5):553-4
88. Weller K, Magerl M, Maurer M. Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. J Eur Acad Dermatol Venereol 2011;25(1):119-20
89. Zanichelli A, Badini M, Nataloni I, et al. Treatment of acquired angioedema with icatibant: a case report. Intern Emerg Med 2011;6(3):279-80
90. Zanichelli A, Bova M, Coerezza A, et al. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012;67(8):1074-7
91. Bygum A, Broesby-Olsen S. Rapid resolution of erythema marginatum after icatibant in acquired angioedema. Acta Derm Venereol 2011;91(2):185-6
92. Agostoni A, Cicardi M, Cugno M, et al. Angioedema due to angiotensin-converting enzyme inhibitors. Immunopharmacology 1999;44(1-2):21-5
93. Banerji A, Clark S, Blanda M, et al. Multicenter study of patients with angiotensin-converting enzyme inhibitor-induced angioedema who present to the emergency department. Ann Allergy Asthma Immunol 2008;100(4):327-32
94. Nielsen EW, Gramstad S. Angioedema from angiotensin-converting enzyme (ACE) inhibitor treated with complement 1 (C1) inhibitor concentrate. Acta Anaesthesiol Scand 2006;50(1):120-2
95. Steinbach O, Schweder R, Freitag B. C1-esterase inhibitor in ACE inhibitor-induced severe angioedema of the tongue. Anaesthesiologie und Reanimation 2001;26(5):133-7
96. Gelee B, Michel P, Haas R, Boishardy F. Angiotensin-converting enzyme inhibitor-related angioedema: emergency treatment with complement C1 inhibitor concentrate. Rev Med Interne 2008;29(6):516-19
97. Stewart M, McGlone R. Fresh frozen plasma in the treatment of ACE inhibitor-induced angioedema. BMJ Case Reports 2012:published online; doi:10.1136/bcr-2012-006849
98. Bas M, Kojda G, Stelter K. Angiotensin-converting enzyme inhibitor induced angioedema : new therapy options. Anaesthesist 2011;60(12):1141-5
99. Schmidt PW, Hirschl MM, Trautinger F. Treatment of angiotensin-converting enzyme inhibitor-related angioedema with the bradykinin B2 receptor antagonist icatibant. J Am Acad Dermatol 2010;63(5):913-14
100. Bas M, Greve J, Stelter K, et al. Therapeutic efficacy of icatibant in angioedema induced by angiotensin-converting enzyme inhibitors: a case series. Ann Emerg Med 2010;56(3):278-82
101. Bernstein J. Evaluation of ecallantide for the acute treatment of Angiotensin Converting enzyme inhibitor induced angioedema (ACE). 2012.Available from: http://clinicaltrials. gov/ct2/show/NCT01036659?% 20term= ecallantide+ACE+% 20inhibitor&rank=1
102. Munchen TU. A melioration of angiotensin converting enzyme inhibitor induced angioedema study. 2011.Available from: http://clinicaltrials. gov/ct2/show/NCT01154361? term=icatibant+ACE%20 +inhibitor&rank=1
103. Cicardi M, Bergamaschini L, Zingale LC, et al. Idiopathic nonhistaminergic angioedema. Am J Med 1999;106(6):650-4
104. Del Corso I, Puxeddu I, Sardano E, et al. Treatment of idiopathic nonhistaminergic angioedema with bradykinin B2 receptor antagonist icatibant. Ann Allergy Asthma Immunol 2012;108(6):460-1
105. Bouillet L, Ponard D, Drouet C, Massot C. Non-histaminic angiodema management: diagnostic and therapeutic interest of tranexamic acid. Rev Med Interne 2004;25(12):924-6
106. Du-Thanh A, Raison-Peyron N, Drouet C, Guillot B. Efficacy of tranexamic acid in sporadic idiopathic bradykinin angioedema. Allergy 2010;65(6):793-5
107. Bork K, Gul D, Dewald G. Hereditary angio-oedema with normal C1 inhibitor in a family with affected women and men. Br J Dermatol 2006;154(3):542-5
108. Agostoni A, Cicardi M. Contraindications to the use of ace inhibitors in patients with C1 esterase inhibitor deficiency. Am J Med 1991;90(2):278
109. Bork K. Diagnosis and treatment of hereditary angioedema with normal C1 inhibitor. Allergy Asthma Clin Immunol 2010;6(1):15
110. Craig T, Riedl M, Dykewicz MS, et al. When is prophylaxis for hereditary angioedema necessary? Ann Allergy Asthma Immunol 2009;102(5):366-72
111. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295(26):1444-8
112. Han Lee ED, Pappalardo E, Scafidi J, Davis AE III. Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice. Immunol Lett 2003;89(2-3):155-60
113. Drouet C, Desormeaux A, Robillard J, et al. Metallopeptidase activities in hereditary angioedema: effect of androgen prophylaxis on plasma aminopeptidase P. J Allergy Clin Immunol 2008;121(2):429-33
114. Spath PJ, Wuthrich B, Butler R. Quantification of C1-inhibitor functional activities by immunodiffusion assay in plasma of patients with hereditary angioedema-evidence of a functionally critical level of C1-inhibitor concentration. Complement 1984;1(3):147-59
115. Frank MM. Hereditary angioedema: short-term prophylaxis for surgery. Allergy Asthma Proc 2012;33(4):303-4
116. Sheffer AL, Fearon DT, Austen KF. Methyltestosterone therapy in hereditary angioedema. Ann Intern Med 1977;86(3):306-8
117. Gelfand JA, Sherins RJ, Alling DW, Frank MM. Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med 1976;295(26):1444-8
118. Fust G, Farkas H, Csuka D, et al. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011;41(3):256-62
119. Cicardi M, Bergamaschini L, Cugno M, et al. Long-term treatment of hereditary angioedema with attenuated androgens: a survey of a 13-year experience. J Allergy Clin Immunol 1991;87(4):768-73
120. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008;100(2):153-61
121. Cicardi M, Castelli R, Zingale LC, Agostoni A. Side effects of long-term prophylaxis with attenuated androgens in hereditary angioedema: comparison of treated and untreated patients. J Allergy Clin Immunol 1997;99(2):194-6
122. Bork K, Pitton M, Harten P, Koch P. Hepatocellular adenomas in patients taking danazol for hereditary angio-oedema. Lancet 1999;353(9158):1066-7
123. Szeplaki G, Varga L, Valentin S, et al. Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema. J Allergy Clin Immunol 2005;115(4):864-9
124. Sloane DE, Lee CW, Sheffer AL. Hereditary angioedema: safety of long-term stanozolol therapy. J Allergy Clin Immunol 2007;120(3):654-8
125. Duck SC, Katayama KP. Danazol may cause female pseudohermaphroditism. Fertil Steril 1981;35(2):230-1
126. Barakat A, Castaldo AJ. Hereditary angioedema: danazol therapy in a 5-year-old child. Am J Dis Child 1993 Sep;147(9):931-2
127. Farkas H. Pediatric hereditary angioedema due to C1-inhibitor deficiency. Allergy Asthma Clin Immunol 2010;6(1):18
128. Farkas K, Terhes G, Deak J, et al. The efficiency of influenza vaccines in patients with inflammatory bowel disease on immunosuppressive therapy. Orv Hetil 2012;153(47):1870-4
129. Farkas H, Czaller I, Csuka D, et al. The effect of long-term danazol prophylaxis on liver function in hereditary angioedema-a longitudinal study. Eur J Clin Pharmacol 2010;66(4):419-26
130. Frank MM, Sergent JS, Kane MA, Alling DW. Epsilon aminocaproic acid therapy of hereditary angioneurotic edema. A double-blind study. N Engl J Med 1972;286(15):808-12
131. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972;287(9):452-4
132. Zanichelli A, Vacchini R, Badini M, et al. Standard care impact on angioedema because of hereditary C1 inhibitor deficiency: a 21-month prospective study in a cohort of 103 patients. Allergy 2011;66(2):192-6
133. Sundstrom A, Seaman H, Kieler H, Alfredsson L. The risk of venous thromboembolism associated with the use of tranexamic acid and other drugs used to treat menorrhagia: a case-control study using the General Practice Research Database. BJOG 2009;116(1):91-7
134. Gower RG, Busse PJ, Aygoren-Pursun E, et al. hereditary angioedema caused by C1-esterase inhibitor deficiency: a literature-based analysis and clinical commentary on prophylaxis treatment strategies. World Allergy Organ J 2011;4(2 Suppl):S9-S21
135. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989;83(3):677-82
136. Farkas H, Csuka D, Zotter Z, et al. Prophylactic therapy in children with hereditary angioedema. J Allergy Clin Immunol 2012;
137. Levi M, Choi G, Picavet C, Hack CE. Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117(4):904-8
138. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011;154(1):81-8
139. Kreuz W, Rusicke E, Martinez-Saguer I, et al. Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012;52(1):100-7
140. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012;125(9):938; e1-7
141. Bouillet L, Longhurst H, Boccon-Gibod I, et al. Disease expression in women with hereditary angioedema. Am J Obstet Gynecol 2008;199(5):484; e1-4
142. Farkas H, Zotter Z, Csuka D, et al. Short-term prophylaxis in hereditary angioedema due to deficiency of the C1-inhibitor-a long-term survey. Allergy 2012;67(12):1586-93
143. Farkas H, Gyeney L, Gidofalvy E, et al. The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures. J Oral Maxillofac Surg 1999;57(4):404-8
144. Bork K, Hardt J, Staubach-Renz P, Witzke G. Risk of laryngeal edema and facial swellings after tooth extraction in patients with hereditary angioedema with and without prophylaxis with C1 inhibitor concentrate: a retrospective study. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011;112(1):58-64
145. Frank MM, Gelfand JA, Atkinson JP. Hereditary angioedema: the clinical syndrome and its management. Ann Intern Med 1976;84(5):580-93
146. Martin L, Degenne D, Toutain A, et al. Hereditary angioedema type III: an additional French pedigree with autosomal dominant transmission J Allergy Clin Immunol 2001;107(4):747-8
147. Bork K. Hereditary angioedema with normal C1 inhibitor activity including hereditary angioedema with coagulation factor XII gene mutations. Immunol Allergy Clin North Am 2006;26(4):709-24
148. Herrmann G, Schneider L, Krieg T, et al. Efficacy of danazol treatment in a patient with the new variant of hereditary angio-oedema (HAE III). Br J Dermatol 2004;150(1):157-8
149. Serrano C, Guilarte M, Tella R, et al. Oestrogen-dependent hereditary angio-oedema with normal C1 inhibitor: description of six new cases and review of pathogenic mechanisms and treatment. Allergy 2008;63(6):735-41
150. Di Leo E, Nettis E, Montinaro V, et al. Acquired angioedema with C1 inhibitor deficiency associated with anticardiolipin antibodies. Int J Immunopathol Pharmacol 2011;24(4):1115-18
151. Szeplaki G, Varga L, Szepvolgyi A, et al. Acquired angioedema associated with primary antiphospholipid syndrome in a patient with antithrombin III deficiency. Int Arch Allergy Immunol 2008;146(2):164-8
152. Frigas E. Angioedema with acquired deficiency of the C1 inhibitor: a constellation of syndromes. Mayo Clin Proc 1989;64(10):1269-75
153. Cugno M, Cicardi M, Agostoni A. Activation of the contact system and fibrinolysis in autoimmune acquired angioedema: a rationale for prophylactic use of tranexamic acid. J Allergy Clin Immunol 1994;93(5):870-6
154. Cicardi M, Bergamaschini L, Cugno M, et al. Pathogenetic and clinical aspects of C1 inhibitor deficiency. Immunobiology 1998;199(2):366-76
155. Obtulowicz K, Kapusta M, Obtulowicz A, Mazurkiewicz A. C1 inhibitor deficiency. Heredity and acquired forms. Symptoms, diagnostic and therapeutic problems. Przegl Lek 2002;59(6):438-41
156. Fonseca Aizpuru EM, Rodriguez Avila EE, Arias Miranda I, Nuno Mateo FJ. Hereditary and acquired angioedema: clinical characteristics in 8 patients and review of the literature. Rev Clin Esp 2009;209(7):332-6
157. Carugati A, Pappalardo E, Zingale LC, Cicardi M. C1-inhibitor deficiency and angioedema. Mol Immunol 2001;38(2-3):161-73
158. Kaplan AP. C1 inhibitor deficiency: hereditary and acquired forms. J Investig Allergol Clin Immunol 2001;11(4):211-19
159. Chevailler A, Arlaud G, Ponard D, et al. C-1-inhibitor binding monoclonal immunoglobins in three patients with acquired angioneurotic edema. J Allergy Clin Immunol 1996;97(4):998-1008
160. Sanchez-Cano D, Callejas-Rubio JL, Lara-Jimenez MA, et al. Successful use of rituximab in acquired C1 inhibitor deficiency secondary to Sjogren's syndrome. Lupus 2008;17(3):228-9
161. Donaldson VH, Bernstein DI, Wagner CJ, et al. Angioneurotic edema with acquired C1- inhibitor deficiency and autoantibody to C1- inhibitor: response to plasmapheresis and cytotoxic therapy. J Lab Clin Med 1992;119(4):397-406
162. Branellec A, Bouillet L, Javaud N, et al. Acquired C1-inhibitor deficiency: 7 patients treated with rituximab. J Clin Immunol 2012;32(5):936-41
163. Hassan A, Amarger S, Tridon A, et al. Acquired angioedema responding to rituximab. Acta Derm Venereol 2011;91(6):733-4
164. Levi M, Hack CE, van Oers MH. Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency. Am J Med 2006;119(8):e3-5
165. Maruta T, Tateishi M, Fujie Y, et al. Anesthesia and perioperative management in a patient with acquired angioedema. Masui 2011;60(7):862-5
166. Beltrami L, Zanichelli A, Zingale L, et al. Long-term follow-up of 111 patients with angiotensin-converting enzyme inhibitor-related angioedema. J Hypertens 2011;29(11):2273-7
167. Cicardi M, Zingale LC, Bergamaschini L, Agostoni A. Angioedema associated with angiotensin-converting enzyme inhibitor use: outcome after switching to a different treatment. Arch Intern Med 2004;164(8):910-13
168. Caldeira D, David C, Sampaio C. Tolerability of angiotensin-receptor blockers in patients with intolerance to angiotensin-converting enzyme inhibitors: a systematic review and meta-analysis. Am J Cardiovasc Drugs 2012;12(4):263-77
169. Berinert P Study of Subcutaneous Versus Intravenous Administration (PASSION). Available from: http://www. clinicaltrials.gov/ct2/show/ NCT00748202?term=hereditary +angioedema&rank=18
170. Subcutaneous CINRYZE with recombinant human hyaluronidase for prevention of angioedema attacks. Available from: http://www. clinicaltrials.gov/ct2/show/ NCT01756157?term=hereditary +angioedema&rank=25
171. AMelioration of angiotensin converting enzyme inhibitor induced angioedema study. 2011. Available from: http://clinicaltrials.gov/ct2/show/ NCT01154361?term=icatibant+ACE%20 +inhibitor&rank=1
172. Evaluation of Ecallantide for the acute treatment of Angiotensin Converting Enzyme inhibitor induced angioedema (ACE). 2012. Available from: http://clinicaltrials.gov/ct2/show/ NCT01036659?%20term=ecallantide +ACE+%20inhibitor&rank=1
173. Prior N, Remor E, Gomez-Traseira C, et al. Development of a disease-specific quality of life questionnaire for adult patients with hereditary angioedema due to C1 inhibitor deficiency (HAE-QoL): spanish multi-centre research project. Health Qual Life Outcomes 2012;10:82